Uncategorized
Imprimis obtains propriety rights for sedation, anesthetic compounded formulations
Imprimis Pharmaceuticals has acquired the rights to novel propriety sedation and analgesic/anesthetic compounded formulations for ophthalmic and other surgical procedures, according to a press release.Variations of the formulations, administered sublingually to block pain and sedate patients, have been used in more than 1,000 cataract and refractive surgeries, co-developer John Berdahl, MD, said in the release.